These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33259959)

  • 41. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
    Catenacci DV; Junttila MR; Karrison T; Bahary N; Horiba MN; Nattam SR; Marsh R; Wallace J; Kozloff M; Rajdev L; Cohen D; Wade J; Sleckman B; Lenz HJ; Stiff P; Kumar P; Xu P; Henderson L; Takebe N; Salgia R; Wang X; Stadler WM; de Sauvage FJ; Kindler HL
    J Clin Oncol; 2015 Dec; 33(36):4284-92. PubMed ID: 26527777
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Topical delivery of vismodegib using ablative fractional laser and micro-emulsion formulation in vitro.
    Olesen UH; Clergeaud G; Lerche CM; Andresen TL; Haedersdal M
    Lasers Surg Med; 2019 Jan; 51(1):79-87. PubMed ID: 30152536
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polymeric micelle nanocarriers for targeted epidermal delivery of the hedgehog pathway inhibitor vismodegib: formulation development and cutaneous biodistribution in human skin.
    Kandekar SG; Singhal M; Sonaje KB; Kalia YN
    Expert Opin Drug Deliv; 2019 Jun; 16(6):667-674. PubMed ID: 30995141
    [No Abstract]   [Full Text] [Related]  

  • 44. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vismodegib, a sonic hedgehog signalling blockade, ameliorates ovalbumin and ovalbumin/lipopolysaccharide-induced airway inflammation and asthma phenotypical models.
    El-Baz LMF; Elaidy SM; Hafez HS; Shoukry NM
    Life Sci; 2022 Dec; 310():121119. PubMed ID: 36306870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma.
    Kumar V; Wang Q; Sethi B; Lin F; Kumar V; Coulter DW; Dong Y; Mahato RI
    Biomaterials; 2021 Nov; 278():121138. PubMed ID: 34634662
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.
    Graham RA; Lum BL; Cheeti S; Jin JY; Jorga K; Von Hoff DD; Rudin CM; Reddy JC; Low JA; Lorusso PM
    Clin Cancer Res; 2011 Apr; 17(8):2512-20. PubMed ID: 21300760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hedgehog-mediated regulation of PPARγ controls metabolic patterns in neural precursors and shh-driven medulloblastoma.
    Bhatia B; Potts CR; Guldal C; Choi S; Korshunov A; Pfister S; Kenney AM; Nahlé ZA
    Acta Neuropathol; 2012 Apr; 123(4):587-600. PubMed ID: 22407012
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular therapy targeting Sonic hedgehog and hepatocyte growth factor signaling in a mouse model of medulloblastoma.
    Coon V; Laukert T; Pedone CA; Laterra J; Kim KJ; Fults DW
    Mol Cancer Ther; 2010 Sep; 9(9):2627-36. PubMed ID: 20807782
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical experience with Hedgehog pathway inhibitors.
    Low JA; de Sauvage FJ
    J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds.
    Yang H; Cong WN; Yoon JS; Egan JM
    Cancer Med; 2015 Feb; 4(2):245-52. PubMed ID: 25354792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tomato Bushy Stunt Virus Nanoparticles as a Platform for Drug Delivery to Shh-Dependent Medulloblastoma.
    Lico C; Tanno B; Marchetti L; Novelli F; Giardullo P; Arcangeli C; Pazzaglia S; Podda MS; Santi L; Bernini R; Baschieri S; Mancuso M
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.
    Kaye SB; Fehrenbacher L; Holloway R; Amit A; Karlan B; Slomovitz B; Sabbatini P; Fu L; Yauch RL; Chang I; Reddy JC
    Clin Cancer Res; 2012 Dec; 18(23):6509-18. PubMed ID: 23032746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Albumin nanoparticles for glutathione-responsive release of cisplatin: New opportunities for medulloblastoma.
    Catanzaro G; Curcio M; Cirillo G; Spizzirri UG; Besharat ZM; Abballe L; Vacca A; Iemma F; Picci N; Ferretti E
    Int J Pharm; 2017 Jan; 517(1-2):168-174. PubMed ID: 27956195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery and preclinical development of vismodegib.
    Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
    Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
    Abou-Alfa GK; Lewis LD; LoRusso P; Maitland M; Chandra P; Cheeti S; Colburn D; Williams S; Simmons B; Graham RA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):29-36. PubMed ID: 28523596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vismodegib for the treatment of basal cell skin cancer.
    Poggi L; Kolesar JM
    Am J Health Syst Pharm; 2013 Jun; 70(12):1033-8. PubMed ID: 23719880
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
    Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH
    N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.